An interventional study of Active Stimulation and Sham Stimulation in Rheumatoid Arthritis, sponsored by Galvani Bioelectronics. Recruiting at 14 sites in 2 countries. Open to participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-22.
Sponsored by Galvani Bioelectronics · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 19th largest by planned enrollment, is one of 2 that started in 2021, is the only one with no phase, and was the 16th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–65
University of Nebraska · Sites in United States
Ages 19+
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 22 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 9
First in 2007; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 290 across the 23 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Galvani Bioelectronics is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Galvani Bioelectronics has 2 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
1 of the studies testing baricitinib in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05003310Galvani BioelectronicsConsideRAte Study - Splenic Stimulation for RA | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories. The study will consist of 4 study periods, including a Randomized Control Trial period (Period 1), an Open Label period (Period 2), a Treat-to-target period (Period 3), and a Long-term Follow-up period (Period 4). Participants eligible for implant will have active rheumatoid arthritis (RA) and have an inadequate response or intolerance to at least two biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) or JAK inhibitors (JAKis). A sufficient number of participants will be enrolled so that approximately 28 participants will undergo device implantation.
Participants with active rheumatoid arthritis (RA) who receive the implantable system will be randomly assigned to receive either active stimulation or sham-stimulation for 12 weeks (Period 1).
Following Period 1, all participants will enter an open label phase (Period 2) during which participants who responded to stimulation will continue on stimulation; whereas participants who received sham stimulation, or were stimulation non-responders, will receive a market-approved RA drug for 12 weeks.
At the end of Period 2, participants who respond to their Period 2 therapy but still exhibit signs and symptoms of RA will enter the Treat-to-target period (Period 3); others will proceed to Period 4 (Long-term Follow-up). During the Treat-to-Target period, participants will be treated with dual therapy (stimulation in combination with the market-approved RA drug) for up to 24 weeks.
Period 4 provides long term safety follow up for all study participants for a period of 5 years. Participants may receive stimulation in combination with other approved and standard of care therapies, subject to a favorable benefit-risk assessment in the judgement of the treating rheumatologist.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active stimulation for 12 weeks
Device: Active Stimulation · Drug: Background Treatment
Sham stimulation for 12 weeks
Device: Sham Stimulation · Drug: Background Treatment
Open label active stimulation for 12 additional weeks
Device: Active Stimulation · Drug: Background Treatment
Open label drug treatment with baricitinib for 12 weeks
Drug: Baricitinib · Drug: Background Treatment
Participants on baricitinib during Period 2 will have active stimulation added for 24 weeks
Device: Active Stimulation · Drug: Baricitinib · Drug: Background Treatment
Participants on active stimulation during Period 2 will have baricitinib added for 24 weeks
Device: Active Stimulation · Drug: Baricitinib · Drug: Background Treatment
Standard of care treatments with or without stimulation
Device: Active Stimulation · Drug: Background Treatment
Stimulation will be turned ON and applied during each day of the period.
Sham stimulation will be provided during the period
Baricitinib (2 mg) is administered daily during the period.
Stable dose of standard background treatment (e.g., csDMARD therapy)
Incidence of Adverse Events [Safety and Tolerability]
Adverse Events (AEs) may include clinically significant findings from Laboratory Safety Assessments (clinical chemistry and hematology), vital signs (blood pressure, heart rate, respiratory rate, and body temperature), and 12-Lead EKG
Time frame: Up through the end of Period 1 (Period 1 is up to 12 weeks duration)
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time frame: During Period 2 (Period 2 is up to 12 weeks in duration beyond Period 1)
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time frame: During Period 3 (Period 3 is up to 24 weeks in duration beyond Period 2)
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time frame: During Period 4 (Period 4 is up to 5 years in duration beyond Period 3)
Change in the 28 Joint Disease Activity Score 28 - C reactive protein (DAS28-CRP)
Time frame: Baseline to 12 weeks (Period 1)
Change in the level of Lipopolysaccharide (LPS)-inducible release of Tumor Necrosis Factor (TNFα) in whole blood assay
Time frame: Baseline to 12 weeks (Period 1)
Change in the level of LPS-inducible release of TNFα in whole blood assay
Time frame: Baseline to 24 weeks (Period 2)
Change in the level of LPS-inducible release of Interleukin 6 (IL-6) in whole blood assay
Time frame: Baseline to 12 weeks (Period 1)
Change in the level of LPS-inducible release of Interleukin 6 (IL-6) in whole blood assay
Time frame: Baseline to 24 weeks (Period 2)
Change in the level of LPS-inducible release of IL-8 in whole blood assay
Time frame: Baseline to 12 weeks (Period 1)
Change in the level of LPS-inducible release of IL-8 in whole blood assay
Time frame: Baseline to 24 weeks (Period 2)
Change in the level of LPS-inducible release of IL-17 in whole blood assay
Time frame: Baseline to 12 weeks (Period 1)
Change in the level of LPS-inducible release of IL-17 in whole blood assay
Time frame: Baseline to 24 weeks (Period 2)
Change in DAS28-CRP
Time frame: Baseline to 24 weeks (Period 2)
Change in DAS28-CRP
Time frame: Baseline to 36 weeks (Period 3)
Change in DAS28-CRP
Time frame: Baseline to 48 weeks (Period 3)
Change in Health Assessment Questionnaire Disability Index (HAQ-DI) score
Time frame: Baseline to 12 weeks (Period 1)
Change in HAQ-DI score
Time frame: Baseline to 24 weeks (Period 2)
Change in HAQ-DI score
Time frame: Baseline to 36 weeks (Period 3)
Change in HAQ-DI score
Time frame: Baseline to 48 weeks (Period 3)
Change in Short Form 36 (SF-36) physical component score
Time frame: Baseline to 12 weeks (Period 1)
Change in SF-36 physical component score
Time frame: Baseline to 24 weeks (Period 2)
Change in SF-36 physical component score
Time frame: Baseline to 36 weeks (Period 3)
Change in SF-36 physical component score
Time frame: Baseline to 48 weeks (Period 3)
Change in SF-36 mental component score
Time frame: Baseline to 12 weeks (Period 1)
Change in SF-36 mental component score
Time frame: Baseline to 24 weeks (Period 2)
Change in SF-36 mental component score
Time frame: Baseline to 36 weeks (Period 3)
Change in SF-36 mental component score
Time frame: Baseline to 48 weeks (Period 3)
Change in SF-36 domain score
Time frame: Baseline to 12 weeks (Period 1)
Change in SF-36 domain score
Time frame: Baseline to 24 weeks (Period 2)
Change in SF-36 domain score
Time frame: Baseline to 36 weeks (Period 3)
Change in SF-36 domain score
Time frame: Baseline to 48 weeks (Period 3)
To evaluate the usability of the external Galvani System devices and accessories
Summarize feedback collected on a questionnaire pertaining to the use of the external Galvani System devices
Time frame: Through 48 weeks
To evaluate the participants' perception of therapy and sensation
A form is provided to participants at each visit after randomization to describe any sensations that may be associated with the Galvani System
Time frame: Through 48 weeks
Evaluate device performance as assessed by tabulation of device deficiencies
Time frame: Through 48 weeks
Change in DAS28-CRP in participants who remain on active stimulation during Period 2
Time frame: week 12 to week 24
Incidence of participants who remain on active stimulation achieving DAS28-CRP score <2.6 at the end of Period 2
Time frame: Time Frame: Week 24
Change in DAS28-CRP in participants who are given Drug treatment with baricitinib during Period 2
Time frame: week 12 to week 24
Incidence of a change in DAS28-CRP greater than 1.2 units in participants who are given Drug treatment with baricitinib during Period 2
Time frame: week 12 to week 24
Incidence of participants who are given drug treatment with baricitinib achieving DAS28-CRP score <2.6 at the end of Period 2
Time frame: Week 24
Not enrolling at this site.
Not enrolling at this site.
Started Oct 2021 (actual). Primary completion is estimated for Jul 2027, 69 months after the start.
Of 56 industry-sponsored interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 92. This study's planned 69 months is above that.
Counting every sponsor, half of 348 studies reached it within 27 months; a quarter within 13 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib
Galvani Bioelectronics